Radiopharmaceuticals for pretargeted PET imaging beyond the barriers (PET Barrier)

Bidragets beskrivning

Positron emission tomography (PET) is an essential method in clinical diagnostics and in drug discovery and development. Nanomedicines and antibody-based therapies are emerging technologies in drug development for treating cancer and neurodegenerative diseases. Nanomedicines and antibodies have typically slow pharmacokinetics, which necessitates use of long living radioisotopes for tracing their distribution with PET. This causes unnecessary radiation burden. The main objective of the project is to develop PET radiopharmaceuticals, which allow pretargeted PET imaging of nanomedicines and antibodies by using short living positron emitters and with lower radiation dose. The developed diagnostics methods will advance development of therapies against cancer and neurodegenerative diseases and can later be utilized in patient stratification for identifying the patients that are most likely to benefit from the therapy.
Visa mer

Startår

2021

Slutår

2025

Beviljade finansiering

Anu Airaksinen Orcid -palvelun logo
600 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Övriga uppgifter

Finansieringsbeslutets nummer

343608

Vetenskapsområden

Kemi

Forskningsområden

Kemia

Identifierade teman

pharmacy, biomedicine